^
    Evidence Level:
    Sensitive: C3 – Early Trials

    [EGFR T790M-Non Small Cell Lung Cancer-osimertinib]

    Source:
    PLoS One
    Test:

    InVisionFirst®-Lung

    Title:
    Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay
    Published date:
    06/11/2020
    Excerpt:
    In EGFR mutant population, acquired T790M was identified by ctDNA assay in 54% (34/63) of patients, all without concurrent tissue genotyping and received matched therapy (osimertinib) solely according to liquid biopsy results. The response rate at 3 months in the whole population was 62%. The response rate at 3 months in the whole population was 62%.
    DOI:
    10.1371/journal.pone.0234302
    Trial ID:
    LIBIL